

## Supplementary References

- w1. Guo D, Lian J, Liu T et al. Contribution of late sodium current (I<sub>Na-L</sub>) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents. *Heart Rhythm* 2011;8:762-9.
- w2. Probst V, Denjoy I, Meregalli PG et al. Clinical aspects and prognosis of Brugada syndrome in children. *Circulation* 2007;115:2042-8.
- w3. Chockalingam P, Wilde AA. Loss-of-Function Sodium Channel Mutations in Infancy: A Pattern Unfolds. *Circulation* 2012;125:6-8.
- w4. Grant AO, Carboni MP, Neplioueva V et al. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *J Clin Invest* 2002;110:1201-9.
- w5. Bezzina C, Veldkamp MW, van den Berg MP et al. A single Na<sup>(+)</sup> channel mutation causing both long-QT and Brugada syndromes. *Circ Res* 1999;85:1206-13.
- w6. Liu JF, Moss AJ, Jons C et al. Mutation-specific risk in two genetic forms of type 3 long QT syndrome. *Am J Cardiol* 2010;105:210-3.
- w7. Medeiros-Domingo A, Kaku T, Tester DJ et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. *Circulation* 2007;116:134-42.
- w8. Chockalingam P, Rammeloo LA, Postema PG et al. Fever-induced life-threatening arrhythmias in children harboring an SCN5A mutation. *Pediatrics* 2011;127:e239-e244.
- w9. Wilde AA, Viskin S. EP testing does not predict cardiac events in Brugada syndrome. *Heart Rhythm* 2011;8:1598-600.
- w10. Brugada R. Sudden death: managing the family, the role of genetics. *Heart* 2011;97:676-81.
- w12. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. *Circulation* 2007;116:1137-44.
- w13. Moreno JD, Clancy CE. Pathophysiology of the cardiac late Na current and its potential as a drug target. *J Mol Cell Cardiol* 2011 In Press.
- w14. Silver ES, Liberman L, Chung WK et al. Long QT syndrome due to a novel mutation in SCN5A: treatment with ICD placement at 1 month and left cardiac sympathetic denervation at 3 months of age. *J Interv Card Electrophysiol* 2009;26:41-5.
- w15. Schwartz PJ. Pharmacological and non-pharmacological management of the congenital long QT syndrome: the rationale. *Pharmacol Ther* 2011;131:171-7.

w16. Postema PG, Wolpert C, Amin AS et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website ([www.brugadadrugs.org](http://www.brugadadrugs.org)). Heart Rhythm 2009;6:1335-41.